Natural Small Molecules in Breast Cancer Treatment: Understandings from a Therapeutic Viewpoint.
Mohammad Rezaul IslamFahadul IslamMohammed H NafadyMuniya AkterSaikat MitraRajib DasHumaira UrmeeSheikh ShohagAklima AkterKumarappan ChidambaramFahad A AlhumaydhiTalhah Bin EmranDaniela Simona CavaluPublished in: Molecules (Basel, Switzerland) (2022)
Breast cancer (BrCa) is the most common malignancy in women and the second most significant cause of death from cancer. BrCa is one of the most challenging malignancies to treat, and it accounts for a large percentage of cancer-related deaths. The number of cases requiring more effective BrCa therapy has increased dramatically. Scientists are looking for more productive agents, such as organic combinations, for BrCa prevention and treatment because most chemotherapeutic agents are linked to cancer metastasis, the resistance of the drugs, and side effects. Natural compounds produced by living organisms promote apoptosis and inhibit metastasis, slowing the spread of cancer. As a result, these compounds may delay the spread of BrCa, enhancing survival rates and reducing the number of deaths caused by BrCa. Several natural compounds inhibit BrCa production while lowering cancer cell proliferation and triggering cell death. Natural compounds, in addition to therapeutic approaches, are efficient and potential agents for treating BrCa. This review highlights the natural compounds demonstrated in various studies to have anticancer properties in BrCa cells. Future research into biological anti-BrCa agents may pave the way for a new era in BrCa treatment, with natural anti-BrCa drugs playing a key role in improving BrCa patient survival rates.
Keyphrases
- breast cancer risk
- papillary thyroid
- cell death
- cell proliferation
- cell cycle arrest
- type diabetes
- pregnant women
- squamous cell carcinoma
- squamous cell
- metabolic syndrome
- mesenchymal stem cells
- stem cells
- young adults
- multidrug resistant
- cell cycle
- endoplasmic reticulum stress
- case report
- bone marrow
- childhood cancer
- drug induced
- combination therapy
- pi k akt